From: Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients
Statistic | Estimate (95 % CI) | P valuea |
---|---|---|
AUC endostatin alone | 0.726 (0.603 to 0.848) | <0.001 |
AUC cystatin C alone | 0.674 (0.535 to 0.812) | 0.01 |
AUC NGAL alone | 0.577 (0.430 to 0.723) | 0.22 |
AUC early oliguria | 0.618 (0.509 to 0.727) | 0.04 |
AUC clinical model | 0.759 (0.646 to 0.872) | <0.001 |
AUC clinical model + endostatin | 0.839 (0.752 to 0.925) | <0.001 |
AUC clinical model + cystatin C | 0.776 (0.662 to 0.890) | <0.001 |
AUC clinical model + NGAL | 0.766 (0.657 to 0.874) | <0.001 |
NRI (endostatin) | 0.268 (0.010 to 0.526) | 0.04 |
IDI (endostatin) | 0.073 (0.038 to 0.142) | 0.04 |
NRI (cystatin C) | 0.06 (−0.16 to 0.28) | 0.63 |
IDI (cystatin C) | 0.012 (−0.013 to 0.037) | 0.34 |
NRI (NGAL) | 0.035 (−0.15 to 0.22) | 0.71 |
IDI (NGAL) | 0.0061 (−0.013 to 0.025) | 0.53 |